
Two recent trials demonstrated the safety and efficacy of risankizumab-rzaa for the treatment of adults with active psoriatic arthritis.... [Read More]
Two recent trials demonstrated the safety and efficacy of risankizumab-rzaa for the treatment of adults with active psoriatic arthritis.... [Read More]
• By Mary Choy, PharmD, BCGP, FASHP
About 30% of patients with psoriasis have psoriatic arthritis (PsA), a complex, multi-faceted, chronic, inflammatory musculoskeletal and skin disease for which the treatment has changed considerably over the past few years.1 Biosimilars and other new drugs have become a therapeutic turning point for many patients suffering from rheumatic illnesses, including PsA. The treatment of PsA… [Read More]
• By From the College
Spurred by a recent Cigna policy, the ACR will lead a resolution to oppose insurance companies providing financial incentives for patients to switch treatments. Several specialties are cosponsoring the resolution for a special meeting of the AMA House of Delegates in June. ... [Read More]
• By From the College
The ACR has sent a letter to Cigna expressing opposition to the initiative, which jeopardizes patients’ health, interferes with medical decision making, undermines the doctor-patient relationship and may disproportionately affect patients of lower socioeconomic status.... [Read More]
• By Reuters Staff
(Reuters)—The U.S. Food and Drug Administration (FDA) on Friday approved AbbVie Inc.’s new treatment for rheumatoid arthritis (RA), a win for the drugmaker seeking to widen its portfolio as its blockbuster flagship therapy Humira (adalimumab) faces competition. The drug, Rinvoq (upadacitinib), is a JAK inhibitor. It is set to compete with Pfizer Inc.’s Xeljanz (tofacitinib)… [Read More]
The FDA has approved rizankixumab to treat adults with plaque psoriasis and added boxed warnings to sleep medications…... [Read More]
Browse and search abstracts from the ACR Convergence and ACR/ARP Annual Meetings going back to 2012.
The Foundation is the largest private funding source for rheumatology research and training in the U.S.
Don’t miss rheumatology’s premier scientific meeting for anyone involved in research or the delivery of rheumatologic care or services.